Biofrontera AG
Ansprechpartner: Investor Relations
Tel.: +49 (0) 214 87 63 20
Business news for the stock market

Biofrontera AG: Employees appeal in own statement to the shareholders not to accept the takeover offer of Deutsche Balaton AG

Leverkusen, Germany (pta/03.08.2022/10:30 UTC+2)

- Employees take a stand on the takeover offer of Deutsche Balaton AG published on July 15, 2022

- Employees appeal to the shareholders of Biofrontera AG NOT to accept the takeover offer

Biofrontera AG (ISIN: DE0006046113), an international biopharmaceutical company, announces that the employees of the Biofrontera Group have issued their own statement on the takeover offer of Deutsche Balaton AG pursuant to Section 27 (2) WpÜG. In this statement, 88 employees (representing 100% of the active employees in Germany) appeal to the shareholders of Biofrontera AG NOT to accept the takeover offer of Deutsche Balaton AG published on July 15, 2022, and at the same time take a position on the election proposals for the elections to the Supervisory Board for the Annual General Meeting on August 23, 2022.

The statement of the employees was attached on August 3, 2022 to the statement of the Management Board, which the Management Board submitted together with the Supervisory Board, and was published on the internet on the website of Biofrontera AG at in the section "Investors" under "Takeover Offer of Deutsche Balaton AG".


About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on US OTC market (BFAGY).

Forward-looking statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "predict", "estimate" and "intend", among others. Such forward-looking statements are based on current estimates and assumptions made by Biofrontera AG's management to the best of its knowledge and belief, which in their opinion are reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, financial condition, performance or achievements of the company or industry to be materially different from any future results, financial condition, performance or achievements expressed or implied by such forward-looking statements. No undue reliance should be placed on such statements. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements.


Emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Contact Person: Investor Relations
Phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (Share)
Stock Exchange(s): Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate
Other Stock Exchanges: US OTC